DR. Falk Pharma GmbH
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Nov 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 6 to 28, 2027 · next Feb 6
- 1 fee due Jun 26, 2027The maintenance fee for Use of nor-ursodeoxycholic acid for reducing liver fat (US 11,850,252) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for ANTI-CD30L Antibodies and Uses Thereof (US 11,866,505) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for A method of treating pancreatitis using 1,4-benzoxazine derivatives. (US 10,611,756) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,000,526 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size In force · USPTO record | In force | USPTO record | |
| US 9,512,167 | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size In force · USPTO record | In force | USPTO record | |
| US 11,352,334 | 3-(5-Chloro-2-Oxobenzo[D]OXAZOL-3(2H)-YL) Propanoic Acid Derivatives as Kmo Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 12,459,906 | 3-(5-Chloro-2-Oxobenzo[D]OXAZOL-3(2H)-YL) Propanoic Acid Derivatives as Kmo Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 9,867,780 | Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus In force · USPTO record | In force | USPTO record | |
| US 10,369,100 | Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus In force · USPTO record | In force | USPTO record | |
| US 10,695,291 | Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus In force · USPTO record | In force | USPTO record | |
| US 11,382,860 | Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus In force · USPTO record | In force | USPTO record | |
| US 9,932,328 | 3-(6-Alkoxy-5-Chlorobenzo[D]ISOXAZOL-3-YL)PROPANOIC Acid Useful as Kynurenine Monooxygenase Inhibitors In force · High confidence | In force | High confidence | |
| US 10,273,232 | 3-(6-Alkoxy-5-Chlorobenzo[D]ISOXAZOL-3-YL)PROPANOIC Acid Useful as Kynurenine Monooxygenase Inhibitors In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 23: 2 patents in force now held by others · 5 lapsed for an unpaid fee · 10 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 abandoned · 2 no status recorded